LEKTI移植的向日三素抑制剂:一种潜在的治疗皮肤疾病的疗法
Jeffrey Mah1, Vignesh Jayarajan1, Xin Huang1
1Institute of Child Health, University College London, 30 Guilford Street, London WC1N 1EH, United Kingdom.
Journal of medicinal chemistry
|November 11, 2025
概括
一种新的选择性Kallikrein 5 (KLK5) 抑制剂,7,被开发用于治疗皮肤屏障功能障碍. 这种强有力的抑制剂通过恢复皮肤完整性,对诸如阿托皮炎 (AD) 等疾病具有前景.
科学领域:
- 生物化学 生物化学
- 皮肤病学 皮肤病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 卡利克林5 (KLK5) 是一种皮肤蛋白酶,通过裂解脱体蛋白来调节屏障功能.
- 升高的KLK5活性会导致过度蛋白质分解,导致皮肤屏障受损,并与阿托皮性皮肤炎 (AD) 有关.
- 现有的血清蛋白酶抑制剂往往缺乏KLK5选择性,需要有针对性的治疗开发.
研究的目的:
- 设计和评估针对Kallikrein 5 (KLK5) 的新型选择性抑制剂.
- 确定一种强效的治疗剂,用于特征是KLK5活性升高和皮肤屏障功能受损的疾病.
主要方法:
- 基于太阳花素抑制剂支架的新型类似物的设计和合成.
- 生物化学试验以确定抑制剂强度 (IC50,Ki) 和针对KLK5.5的选择性.
- 在体外研究中,使用患者衍生的角质细胞来评估KLK5活性和上皮屏障完整性 (超皮电阻).
主要成果:
- 化合物7被证明具有强效 (IC50 = 14 ± 4 nM; Ki = 11 nM) 和选择性抑制KLK5.
- 在尼瑟顿综合征患者的角质细胞中,7显著降低了KLK5活性.
- 用7治疗改善了上皮质屏障的完整性,这可以通过增加过体电阻来证明.
结论:
- 7代表了一个有前途的治疗候选人,用于管理与KLK5活动升高相关的条件.
- 选择性KLK5抑制剂的开发,如7,为恢复皮肤屏障完整性提供了一个潜在的策略,在诸如阿托皮炎等疾病中.
更多相关视频
11:13Adenoviral Gene Therapy for Diabetic Keratopathy: Effects on Wound Healing and Stem Cell Marker Expression in Human Organ-cultured Corneas and Limbal Epithelial Cells
Published on: April 7, 2016
9.5K
08:06Y-27632 Enriches the Yield of Human Melanocytes from Adult Skin Tissues
Published on: July 8, 2020
6.0K
相关概念视频
01:19Clinical Applications of Epidermal Stem Cells
3.2K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
3.2K
00:59Gene Therapy
27.3K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.3K